Zevra Therapeutics (ZVRA) Stock Forecast & Price Target $10.52 -0.17 (-1.59%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Zevra Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 8 Analyst RatingsSell1Hold1Buy6 Based on 8 Wall Street analysts who have issued ratings for Zevra Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 1 has given a sell rating, 1 has given a hold rating, and 6 have given a buy rating for ZVRA. Consensus Price Target $24.00128.14% Upside According to the 8 analysts' twelve-month price targets for Zevra Therapeutics, the average price target is $24.00. The highest price target for ZVRA is $29.00, while the lowest price target for ZVRA is $18.00. The average price target represents a forecasted upside of 128.14% from the current price of $10.52. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for ZVRA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Zevra Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZVRA Analyst Ratings Over TimeTypeCurrent Forecast10/14/24 to 10/14/251 Month Ago9/14/24 to 9/14/253 Months Ago7/16/24 to 7/16/251 Year Ago10/15/23 to 10/14/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)Buy6 Buy rating(s)8 Buy rating(s)8 Buy rating(s)7 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$24.00$23.71$23.71$20.83Forecasted Upside128.14% Upside205.99% Upside92.49% Upside157.84% UpsideConsensus RatingModerate BuyModerate BuyBuyBuy ZVRA Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ZVRA Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Zevra Therapeutics Stock vs. The CompetitionTypeZevra TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.63 2.33 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside124.51% Upside1,004.40% Upside14.04% UpsideNews Sentiment RatingPositive NewsSee Recent ZVRA NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/14/2025Weiss Ratings0 of 5 stars Reiterated RatingSell (D+)8/18/2025Zacks Research0 of 5 stars DowngradeStrong-Buy ➝ Hold8/13/2025Citigroup3 of 5 stars Reiterated RatingOutperform8/13/2025JMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJason N.Subscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetMarket Outperform$19.00 ➝ $18.00+94.55%7/10/2025Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingK. KluskaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$25.00 ➝ $29.00+150.86%7/2/2025HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrandon FolkesSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$26.00+190.50%3/13/2025Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSumant KulkarniSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$23.00 ➝ $25.00+213.28%3/13/2025GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingE. HickmanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$20.00 ➝ $22.00+183.83%9/24/2024Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$19.00 ➝ $21.00+177.04%9/24/2024Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$18.00 ➝ $25.00+229.82% Get the Latest News and Ratings for ZVRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/30/2024William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingS. CorwinSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-BuyAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:55 PM ET. ZVRA Forecast - Frequently Asked Questions What is Zevra Therapeutics' forecast for 2025? According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Zevra Therapeutics is $24.00, with a high forecast of $29.00 and a low forecast of $18.00. Should I buy or sell Zevra Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last twelve months. There is currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ZVRA shares. Does Zevra Therapeutics's stock price have much upside? According to analysts, Zevra Therapeutics's stock has a predicted upside of 128.14% based on their 12-month stock forecasts. Has Zevra Therapeutics been downgraded by Wall Street analysts recently? Over the previous 90 days, Zevra Therapeutics's stock had 1 downgrade by analysts. What analysts cover Zevra Therapeutics? Zevra Therapeutics has been rated by research analysts at Citigroup, JMP Securities, Weiss Ratings, and Zacks Research in the past 90 days. Do Wall Street analysts like Zevra Therapeutics more than its competitors? Analysts like Zevra Therapeutics more than other "medical" companies. The consensus rating for Zevra Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ZVRA compares to other companies. Stock Forecasts and Research Tools Related Companies ANIP Stock Forecast OCUL Stock Forecast VERA Stock Forecast TWST Stock Forecast APGE Stock Forecast ABCL Stock Forecast DYN Stock Forecast IMCR Stock Forecast TLRY Stock Forecast HROW Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:ZVRA) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhy Wall Street is piling into the “Debasement Trade”Wall Street is piling into what insiders are calling the “Debasement Trade” — and according to former Goldman ...Stansberry Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
